Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a CKD-330 Versus Amlodipine Monotherapy in Hypertensive Patients Inadequately Controlled by Amlodipine Monotherapy

NCT02586311 is registered in ClinicalTrials.gov with Chong Kun Dang Pharmaceutical as lead sponsor.

NCT NCT02586311
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02586311 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a CKD-330 Versus Amlodipine Monotherapy in Hypertensive Patients Inadequately Controlled by Amlodipine Monotherapy
Lead sponsor
Chong Kun Dang Pharmaceutical
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2016
Completion date
September 30, 2016
Enrollment
160 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension